Search

Displaying results 2181 - 2190 of 10000 in total
  1. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 … Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV).

    Categories: Antivirals used in combination for the treatment of HIV infections
  2. Drug

    Nisoldipine

    go.drugbank.com/drugs/DB00401
    Approved

    Nisoldipine may be used in alone or in combination with other agents in the management of hypertension. … By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.

    International brands: Ji Ni Le Er
  3. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    The reacting solution is chilled to precipitate the PETN. … It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395].

    Synonyms: TEN, Tetranitrato de pentaeritritilo
  4. Drug

    Ursodeoxycholic acid

    go.drugbank.com/drugs/DB01586
    ApprovedInvestigational

    [A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by 7b-epimerization of [chenodeoxycholic acid], which is a primary bile acid.

    Products: T-RUXICO
  5. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    zone lymphoma in selected patients. … [L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure

  6. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsProducts: INVEGA SUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 25MG, INVEGASUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 75 MG
  7. Drug

    Sildenafil

    go.drugbank.com/drugs/DB00203
    ApprovedInvestigational

    and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614 … The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension

  8. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Azficel-T is marketed in the US as Laviv for intradermal injection. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

    Synonyms: Azficel-T
  9. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. … Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667]

    Categories: Androgen Receptor Antagonists, Androgen Receptor Inhibitors
  10. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.